X.T.L. Biopharmaceuticals Ltd ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Nasdaq Listing Compliance Status QuarterlyTarget: Full compliance with Nasdaq Listing Rules 5101, 5550(b)(1), 5550(a)(2), and 5250(c)(1)
Psyga Bio Ltd. Acquisition Closing AnnuallyTarget: 100% acquisition of Psyga Bio Ltd. share capital
Clinical Trial Initiations (Psyga Pipeline) Annually0.0Target: Commencement of at least 3 human clinical trials within 12 months of closing
Watch Items
- Nasdaq Delisting Hearing Panel DecisionTrigger: Failure to complete the Psyga Transaction and demonstrate compliance by June 30, 2026Action: Appeal or prepare for transition to OTC market trading
- Form 20-F Filing DelayTrigger: Continued failure to file the Annual Report on Form 20-F for the year ended December 31, 2025Action: Submit written views and request an extended stay of suspension from the Nasdaq Hearings Panel
- Insolvency of The Social Proxy Ltd.Trigger: Liquidation proceedings and trustee appointment ordered by Israeli courtAction: Evaluate recovery of the $1.5 million loan extended to the subsidiary
Research as of 20 Jun 2026